Patents by Inventor Walter Storkus

Walter Storkus has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240252608
    Abstract: The invention provides a peptide derived from the interleukin-13 receptor ?2, which serves as a HLA-A2-restricted cytotoxic T lymphocyte (CTL) epitope. The invention can be used as a vaccine for glioma and can be formulated into compositions for medical or veterinary use. In addition, the invention provides the use of a peptide derived from the Eph family of tyrosine kinase receptors which can be also used as a vaccine for glioma and can be formulated into compositions for medical or veterinary use.
    Type: Application
    Filed: June 28, 2023
    Publication date: August 1, 2024
    Inventors: Hideho OKADA, Walter STORKUS
  • Publication number: 20070167375
    Abstract: The invention provides a peptide derived from the interleukin-13 receptor ?2, which serves as a HLA-A2-restricted cytotoxic T lymphocyte (CTL) epitope. The invention can be used as a vaccine for glioma and can be formulated into compositions for medical or veterinary use. In addition, the invention provides the use of a peptide derived from the Eph family of tyrosine kinase receptors which can be also used as a vaccine for glioma and can be formulated into compositions for medical or veterinary use.
    Type: Application
    Filed: September 21, 2005
    Publication date: July 19, 2007
    Applicant: University of Pittsburgh of the Commonwealth System of Higher Education
    Inventors: Hideho Okada, Walter Storkus, Junichi Eguchi, Hidemitsu Sato
  • Publication number: 20060019899
    Abstract: EphA2 T-cell epitope are provided herein. The epitopes include peptides corresponding to specific fragments of human EphA2 protein containing one or more T-cell epitopes, and conservative derivatives thereof. The EphA2 T-cell epitopes are useful in an assay, such as an ELISPOT assay, that may be used to determine and/or quantify a patient's immune responsiveness to EphA2. The epitopes also are useful in methods of modulating a patient's immune reactivity to EphA2, which has substantial utility as a treatment for cancers that overexpress EphA2, such as renal cell carcinoma (RCC). The EphA2 epitopes also can be used to vaccinate a patient against EphA2, by in vivo or ex vivo methods.
    Type: Application
    Filed: September 23, 2005
    Publication date: January 26, 2006
    Applicants: University of Pittsburgh, Medimmune, Inc.
    Inventors: Walter Storkus, Michael Kinch
  • Publication number: 20050170503
    Abstract: Antigen-specific T-cells prepared by culturing T-cells in formulations comprising combinations of DCs and either tumor cells or virally infected cells are disclosed. These formulations generally comprise hybridoma of at least one dendritic cell fused to either at least one tumor cell or at least one virally infected cell, or co-cultures of dendritic cells and either tumor cells or virally infected cells. The resulting T-cells can then be used in immunotherapy methods through adoptive transfer of autologous antigen-specific T-cells into patients using well-established techniques, as agents to identify tumor antigens, and to establish animal models.
    Type: Application
    Filed: March 28, 2005
    Publication date: August 4, 2005
    Inventors: Louis Falo, Walter Storkus
  • Publication number: 20050048550
    Abstract: EphA2 T-cell epitope agonists are provided herein. The agonists include peptides corresponding to specific fragments of human EphA2 protein containing one or more T-cell epitopes, and conservative derivatives thereof. The EphA2 T-cell epitope agonists are useful in an assay, such as an ELISPOT assay, that may be used to determine and/or quantify a patient's immune responsiveness to EphA2. The agonists also are useful in methods of modulating a patient's immune reactivity to EphA2, which has substantial utility as a treatment for cancers that overexpress EphA2, such as renal cell carcinoma (RCC). The EphA2 agonists also can be used to vaccinate a patient against EphA2, by in vivo or ex vivo methods.
    Type: Application
    Filed: July 22, 2004
    Publication date: March 3, 2005
    Applicants: University of Pittsburgh-of the Commonwealth System of Higher Education, Medimmune, Inc.
    Inventors: Walter Storkus, Michael Kinch